Long-term (96-week) Efficacy and Safety After Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) in HIV-infected, Virologically Suppressed Adults

Francois Raffi, Chloe Orkin, Amanda Clarke, Laurence Slama, Joel Gallant, Eric Daar, Keith Henry, Jorge Santana-Bagur, David K. Stein, Nicholaos Bellos, Anthony Scarsella, Mingjin Yan, Michael E. Abram, Andrew Cheng, Martin S S Rhee

Research output: Contribution to journalArticlepeer-review

Abstract

ABSTRACT:: In a double-blind, phase 3 trial, 663 HIV-infected, virologically suppressed adults were randomized to switch to tenofovir alafenamide (TAF; n=333) vs. remain on tenofovir disoproxil fumarate (TDF; n=330), each coformulated with emtricitabine (FTC), while continuing their third agent (boosted protease inhibitor or unboosted third agent). At week 96, 88.6% on FTC/TAF and 89.1% on FTC/TDF had HIV-1 RNA <50 copies/mL (adjusted difference -0.5%; 95%CI [-5.3%, 4.4%]). Proteinuria, albuminuria, proximal renal tubular function, and bone mineral density improved after switching to TAF- from TDF-containing regimens. These longer-term data support FTC/TAF as a safe, well tolerated, and durable nucleotide reverse transcriptase inhibitor backbone.

Original languageEnglish (US)
JournalJournal of Acquired Immune Deficiency Syndromes
DOIs
StateAccepted/In press - Mar 6 2017

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Long-term (96-week) Efficacy and Safety After Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) in HIV-infected, Virologically Suppressed Adults'. Together they form a unique fingerprint.

Cite this